Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

Conclusions Sipuleucel-T stimulates long-lived immune responses that translate into long-term clinical benefit. The treatment course (three infusions at weeks 0, 2, and 4) is associated with manageable side effects. Short-term markers of future benefit would be clinically useful, and information on effective treatment combinations or sequences is awaited. Patient summary Sipuleucel-T treatment directs the patient’s own immune system to target and remove prostate cancer cells and increases life expectancy. Patients whose cancer is less advanced generally have a more ‘active’ immune system and may benefit the most from this treatment.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research